Evidence map›Paper›PMID 36786996›Full record

ArticleDoklady. Biochemistry and biophysics2022

Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer.

I V Balalaeva, L V Krylova, M A Karpova, A A Shulga, E V Konovalova, E L Guryev, S M Deyev

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

I V BalalaevaLobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia. irin-b@mail.ru.
L V KrylovaLobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
M A KarpovaLobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
A A ShulgaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
E V KonovalovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia.
E L GuryevLobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
S M DeyevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia. biomem@mail.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of combined schemes for the treatment of oncological diseases is a promising strategy to improve the effectiveness of antitumor therapy. This paper shows the fundamental possibility of multiplying the antitumor effect by combining targeted and photodynamic therapy. It was demonstrated that sequential treatment of HER-2 positive breast cancer cells with the targeted toxin DARPin-LoPE and the photoactive compound photodithazine leads to a synergistic enhancement of their effect. In the future, this approach is intended to achieve the maximum therapeutic effect while minimizing the risks of negative side effects.

Indexed as

NeoplasmsPhotochemotherapyCell Line, TumorErb-b2 Receptor Tyrosine KinasesErb-b2 Receptor Tyrosine Kinasesbreast cancerDARPin-LoPEHER2 receptorphotodithazinephotodynamic therapyrecombinant anticancer toxintargeted therapy

Identifiers

PMID36786996

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.